Alector

"In my years working as a research nurse, I witnessed firsthand the despair that can come when no treatments are available or when one has exhausted all standard treatments. Research provides hope to families." Grace Mausisa, Patient Engagement Lead, says of her career journey to working in biotech. She shares more about the impact of her work at Alector below.

DYK: Alois Alzheimer described three key pathologies (amyloid plaques, tau tangles and dysfunctional glia) in #Alzheimers disease (AD) 100+ years ago? At Alector, we’re working at the intersection of human genetics and neuroscience to harness the power of microglia in the brain’s immune system to counteract neurodegenerative diseases, like AD. Our TREM2 program is the most advanced clinical program of this investigational pathway seeking to enhance microglia activity. Click through below to learn more about TREM2.

As a caregiver for someone with #dementia, getting ahead of financial and legal plans allows your loved one to express wishes for future care and decisions. Click through below for some ideas on where to get started, and visit the Alzheimer's Association®'s Financial & Legal planning guide for more. https://lnkd.in/eh-wDucJ

Alector was a proud sponsor of the Alzheimer's San Diego's Walk4ALZ again this year! Thank you to Alz SD for another inspiring, successful event to raise funds for local Alzheimer’s support and research.

Of the 90 surveyed in our recent #FTD caregiver survey, 44% stressed the importance of caregiver support programs but noted utilization barriers such as affordability. VP of Clinical Development Tiffany Chow recently went through this and other important findings from our recent survey with CheckRare. Listen on their website below.

For our next Alzheimer's Foundation of America Educating America stop this year, we were excited to connect with local community members in New Haven, CT. It has been another successful year being a proud sponsor of the Educating America Tour and its mission to provide free, accessible resources to those impacted by #Alzheimers and other dementias. We're looking forward to our last event of the year next month in Tulsa, OK.

Recently, we were honored to join the Alzheimer's Foundation of America for a corporate sponsors and exhibitors event in New York City. Thank you to AFA President and CEO Chuck Fuschillo, Corporate Partners and Grants Administration Josie Di Chiara, and the rest of the incredible AFA team for all their work to support members of the #dementia community. We are proud to continue to support incredible advocacy organizations like the AFA!

At Alector, our work environment is proof you can give team members flexibility and hybrid work options while still cultivating an engaging, people-first culture. We recently hosted a virtual game show through The Go Game, allowing employees to recharge and connect with colleagues in a relaxed, unique way. Check out some highlights from our event!

Sara Kenkare-Mitra PhD has dedicated her career to developing novel drugs and personalizing treatments for patients in need of new options. As Alector President and Head of R&D, she has been a crucial part of our corporate and clinical progress over the last several years. We are thrilled to share that Sara has been named to this year's #PV100 list, recognizing the most inspiring people in the life sciences industry. Congratulations, Sara! https://lnkd.in/g6g_5JyJ

In recent years, our industry has seen a strong emphasis on improved research and drug development in the neuroscience space. Earlier this week, Alector's President and Head of R&D, Sara Kenkare-Mitra PhD, joined industry leaders to discuss the evolving neurodegenerative therapeutic landscape during the #FierceBiotechSummit "Revival in Neuro Therapeutics" panel. Thank you to Fierce Biotech for hosting an impactful event!